NCT02907567View on ClinicalTrials.gov

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

August 24, 2017

Study Completion Date

September 30, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

CT1812

Active study drug

DRUG

Placebo

non-active study drug

Trial Locations (4)

3050

The Royal Melbourne Hospital Hospital, Parkville

3079

Austin Health, Ivanhoe

3121

Epworth Hospital, Melbourne

Unknown

Dr. Phillip Morris, Southport

Sponsors
All Listed Sponsors
lead

Cognition Therapeutics

INDUSTRY

NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter